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Norman Salem Jr* and Connye N KuratkoAbstract
It has proven difficult to compare the bioavailability of krill oil (KO) vs. fish oil (FO) due to several of the
characteristics of KO. These include the lower concentration of the active ingredients, eicosapentaenoic acid (EPA,
20:5n-3) and docosahexaenoic acid (DHA, 22:6n3), in KO as well as differences in their ratio relative to FO as well as
the red color due to astaxanthin. In addition, the lipid classes in which EPA and DHA are found are quite different
with KO containing phospholipid, di- and tri-glycerides as well as non-esterified fatty acid forms and with FO being
primarily triglycerides. No human study has yet been performed that matches the dose of EPA and DHA in a
randomized, controlled trial with measures of bloodstream EPA and DHA content. However, several claims have
been made suggesting greater bioavailability of KO vs. FO. These have largely been based on a statistical argument
where a somewhat lower dose of KO has been used to result in a similar bloodstream level of EPA and/or DHA or
their total. However, the magnitude of the dosage differential is shown to be too small to be expected to result in
differing blood levels of the long chain n-3 PUFAs. Some studies which have claimed to provide equal doses of KO
and FO have actually used differing amounts of the two major n-3 fatty acid constituents. It is concluded that there
is at present no evidence for greater bioavailability of KO vs. FO and that more carefully controlled human trials
must be performed to establish their relative efficacies after chronic administration.
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Modern diets particularly in the Western world are
largely insufficient in the long chain omega-3 fatty acids
eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA) [1] leading to sub-optimal organ function and an
increased risk of disease [2]. This has led many expert
bodies to make recommendations for increasing intakes
of these vital nutrients either from an increased seafood
intake or via supplements. However, seafood intake in
the Western world is low and as a result EPA and DHA
intake in the US, for example, is only about 30 and
60 mg/d, respectively, on average [3]. Thus, in order to
increase intake of these nutrients, either enriched foods
or high quality supplements containing EPA and DHA
would be needed by many consumers. Industry has pro-
vided fish oils (FO), algal oils and krill oil (KO) capsules to
fulfill this requirement. The EPA and DHA delivered in
fish oil and algal oil is largely in the form of triglycerides
whereas krill oil has triglyceride but also phospholipid and
non-esterified fatty acid forms of these nutrients. Recent* Correspondence: norman.salem@dsm.com
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article, unless otherwise stated.studies such as the one presented by Ramprasath et al. [4]
have claimed that EPA and DHA in krill oil are more bio-
available or more efficiently absorbed than EPA/DHA in
fish oils, presumably due to the phospholipid form of the
lipids in KO. A greater bioavailability would translate into
a higher tissue content of EPA and DHA and a resulting
greater health benefit. However, it is contended here that
this has not in fact been demonstrated due to study design
limitations in this and other previous studies, as will be
discussed below.Discussion
Ramprasath et al. [4] state in their original paper that
“none of the studies managed to show improvement in
the absorption of n-3 fatty acids with krill oil over fish
oil”. They criticize the absence of a randomized, con-
trolled trial design and the use of single dose or short
term supplementation periods. Clinical studies which are
double blinded, randomized and controlled prevent the
introduction of biases. It is also not valid to interpret
differing absorption characteristics of a single dose or a
short term supplementation as relevant to the efficacy of
various supplements which are to be given chronically.entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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pared to FO for its ability to change bloodstream fatty acid
profiles used such approaches. Faced with the lower con-
tent of EPA and DHA in KO relative to FO, researchers
did not attempt to provide equivalent fatty acid doses.
Rather they provided less EPA/DHA in the KO capsules
relative to the FO capsules and then argued that the KO
was more bioavailable when the results showed similar
blood levels of EPA and DHA. Table 1 provides a sum-
mary of key features of several of these human studies.
One example of this is given by the study of Ulven et al.
[5] where three commercial FO capsules containing a total
of 864 mg of EPA/DHA were compared to six KO capsulesTable 1 Study characteristics of comparisons of krill oil and f
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cant 12% increase in arachidonic acid (ARA) whereas the
FO group exhibited a 14% decrease. ARA and its eicosa-
noid products are important biomediators including their
modulation of thrombotic effects and a lowering of ARA
in adults is considered beneficial [6]. The authors conclude
that “these findings indicate that the bioavailability of n-3
PUFAs from krill oil (mainly PL) is as, or possibly more,
efficient as n-3 PUFA from fish oil (TG)”.
Similarly Maki et al. [7] in a randomized, controlled study
of 76 obese adults given 2 g/d of KO, FO or olive oil for 4
wks provided similar amounts of EPA (216 vs. 212 mg/d)
but more DHA in the FO group (90 vs. 178 mg/d). Again
the plasma EPA and DHA were significantly increased in
both the KO and FO groups relative to an olive oil control
group but the two supplemented groups were the same
from a statistical standpoint. It should be noted however
that the increased DHA provided in the FO did result in a
66% greater increase in plasma DHA from the baseline
value (149.9 vs. 90.2) relative to the KO group. The baseline
values for EPA and particularly for DHA were much higher
in the KO group than control suggesting that there were
differences in diet or supplement use in that group relative
to other subjects in the study. It is important in this type of
study to exclude those subjects who take omega-3 supple-
ments or eat large amounts of fish. It is also a good practice
to collect food records or conduct food surveys of the pa-
tients in the study to assess omega-3 PUFA intake.
This, together with the variability in the study obviated
the attainment of statistically significant differences be-
tween groups.
In an acute study where KO was compared to a FO over
72 h in a cross-over trial in 12 healthy, young men, no sta-
tistically significant differences were observed in EPA,
DHA or the sum of EPA +DHA in plasma phospholipids
after giving a closely matched amount (1680 mg) of EPA/
DHA [8]. There was only a 14 d wash out between the
various legs of this trial and it is questionable whether this
period is adequate for wash out. Again, although the au-
thors indicate a double-blinded trial, they provided 14
capsules for the KO and only 4 capsules for the FO or FO
ethyl ester arms. The (probable) difference in color as well
as the different number of capsules preclude the possibil-
ity of a double-blinded study, potentially introducing bias.
There has been a very recent publication evaluating
the efficacy of various sources of long chain omega-3
PUFAs when given at the doses recommended by their
manufacturer [9]. This was an open label, randomized,
cross-over study of 35 healthy subjects. The following
sources were compared with the indicated EPA and
DHA contents: concentrated triglyceride EPA 650, DHA
450 mg; fish oil ethyl ester EPA 756, DHA 228 mg; krill
oil phospholipid EPA 150, DHA 90 mg; salmon oil tri-
glyceride EPA 180, DHA 220 mg. As may be expected,the sources for which larger doses of EPA and DHA
were delivered led to a higher content of EPA and DHA
in whole blood after a 28 day exposure to the various
supplements. For example, the whole blood EPA level
was four-fold higher in the subjects given a concentrated
triglyceride form of fish oil relative to the KO group.
The authors also comment that various risk factors for
cardiovascular disease were reduced best by this concen-
trated form of omega-3 PUFA but the less concentrated
forms like the KO were relatively unsuccessful. Some
effort was made to extrapolate the data to a standardized
dosage of 1000 mg of EPA + DHA/d but the authors in-
dicate that “because of the difficulties encountered in
data extrapolation, i.e. the inaccuracies inherent in the
methodology, given the negative results for some sub-
jects, a statistical analysis of this data was not considered
to be warranted”. They go on to conclude that “”a head-
to-head comparison of the supplements utilized in this
trial, at equivalent doses of EPA + DHA, would be useful
in determining their relative bioavailability and their effi-
cacy in increasing blood levels of omega-3 fatty acids,
and in reducing CVD risk”. In another interesting note,
these authors point out that some individuals actually
had a decrease in blood EPA and DHA during supple-
mentation indicating that they were not consuming their
capsules. Thus the monitoring of compliance by inter-
view, by capsule counts and via fatty acid analysis should
always be a feature of these types of clinical trials. The
authors suggest that one explanation for the decline in
EPA and DHA content in some of these subjects may be
due to their habitual intake of high amounts of these nu-
trients thru seafood in their diets. Once this trial began,
they were asked to stop this seafood intake and the
amount of EPA and DHA in the supplement was actu-
ally less than their previous intake, thus leading to a de-
cline in their blood levels. Here again, it would be
important to exclude those subjects consuming large
amounts of EPA and DHA thru diet or via supplements.
A recent animal study has also made the claim of
greater KO bioavailability relative to FO based on provi-
ding a lower dose and then finding a statistically similar
plasma and liver content of EPA and DHA [10]. In fact,
there was again a higher mean content of EPA in both tis-
sues in the FO group with a substantial difference in liver
but the differences with respect to KO did not reach sta-
tistical significance as there was considerable variability in
measures and a small number of animals in these experi-
mental groups, an n = 6.
Ramprasath et al. [4] recognized that previous studies
failed to show differences in bioavailability or sustained
changes in tissue fatty acid composition after chronic
exposure to FO or KO. They performed a randomized,
cross-over trial in 24 healthy young adults over a period
of 4 wks. They purported to study the same dose of the
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the higher FO content of EPA and DHA by blending the
FO with corn oil [11]. Their claim of performing a trial
with matched omega-3 oils is questionable since, as
pointed out by Nichols et al. the KO contained 114 mg
greater EPA + DHA than the FO dose [12]. According to
the data presented by Ramprasath in their Table six, the
FO contained 13.5% of the fatty acids as EPA as com-
pared to 16.4% in KO and 8.7% DHA as compared to
9.5% in the KO [4]. This translates, assuming that the
same total amount of oil is given in each supplement, to
an increase of 22% (16.44/13.46) in the EPA and 9.5%
(9.46/8.66) in the DHA in the KO capsules relative to
the FO capsules. That the DPAn-3 was slightly higher in
the FO is not an equalizer since the main parameters to be
compared were EPA and DHA as well as their sum in
plasma and RBC. It should be apparent then that the doses
of EPA/DHA were not the same between study arms.
In summary, the argument put forth in many of the
KO studies is that if a lower dose of KO is given relative
to that in the FO, and if this results in statistically the
same EPA or DHA content in the bloodstream, the KO
must have been more bioavailable or more efficacious.
This seems to make sense to the non-scientist but is in
fact based on a statistical argument. The argument makes
the assumption that the differences in EPA/DHA dosage
are of a magnitude such that they would be expected to
result in a statistically significant difference in mean EPA,
DHA or EPA +DHA content in plasma or other blood
compartment. However, it is quite common that even very
substantial differences in omega-3 dosing, although it may
indeed lead to a quite different mean value for EPA or
DHA, do not produce a statistically significant difference.
Some examples of this are in order. In dose-response
studies of FO supplementation, for example, we can com-
pare various doses given within the same study to see how
much of an increase in dose is required before an in-
creased mean value of plasma EPA or DHA becomes sta-
tistically significant in similarly sized studies.
Barcelo-Coblijn et al. conducted a study of 62 fire-
fighters divided into six experimental groups where the
time course of n-3 fatty acid content in RBC was mea-
sured biweekly over 12 wks at a daily FO dose of either
0.6 or 1.2 g/d [13]. The total RBC n-3 fatty acid content
was about the same between these two groups after 2
wks and began to diverge between 4-8 wks only to con-
verge at the same mean value after 10 wks. Although
there was a two-fold difference in FO dose, the differ-
ence in mean values at the 4 wk time point, for example,
was only approximately 7%.
An even more instructive finding was obtained by
Flock et al. in a dose-response study of 300, 600, 900
and 1800 mg/d of FO given daily to 115 healthy men for
5 months with measurements of RBC fatty acid content[14]. Their data for RBC EPA and DHA content is pre-
sented in Table 2. Inspection of this data demonstrates
that if 300 and 600 mg/d FO doses are compared, there is
an increase in the mean values for RBC EPA and DHA
but these changes are not significantly different. The con-
tent of EPA and DHA increase regularly with dose con-
sumed but it is apparent that there is not a linear increase.
Note for example the much greater increase in RBC DHA
when subjects are given the first 300 mg increment (1.43)
than the second such increment (0.30). When the RBC
EPA and DHA contents for the 600 and 900 mg/d doses
are compared, there is again no statistical significance to
the change in mean values. In this study, differences in
EPA +DHA dosages of 600 mg/d were necessary to lead
to statistically significant changes in mean values for EPA
or DHA, i.e., statistical significance was reached for ex-
ample between 300 and 900 mg/d of FO. This is not to in-
dicate that smaller differences in doses cannot lead to
significant changes in bloodstream EPA or DHA content
in a particular trial. The contention is that the statistical
significance of mean differences will depend upon the
supplement dose, length of treatment, number of subjects
in the groups, compliance with study protocols, control of
diets and the variability of analytical measurements. It also
points to the conclusion that the most reasonable design
for a study comparing two sources of EPA and DHA dif-
fering in lipid class is one where identical amounts of both
EPA and DHA are given. If one of the sources then pro-
duced a statistically different content of EPA or DHA,
then a valid claim could be made concerning efficacy or
bioavailability. It is important though to note that the dif-
ferences in the KO vs. FO trials are less than 600 mg and
so it is doubtful that one could expect a difference in EPA
or DHA content. Therefore, the fact that the final com-
position of EPA, DHA or EPA +DHA was statistically
speaking the same even though in many cases less KO
dose was given, was to be expected and has no implica-
tions for bioavailability. Trials based on this premise can-
not conclude that KO is more bioavailable than FO.
Nichols et al. [12] suggested that Ramprasath et al. [4]
had introduced an inappropriate variable into their study
as the FO capsules contained over 32% of their fatty acids
as linoleic acid (18:2n-6, LA). In a response, Ramprasath
et al. [11] indicated that they had blended the FO with
corn oil in an attempt to equalize the levels of EPA and
DHA in the two oils and conceded that this may have in-
fluenced their results. If LA was 32.5% of the fatty acid
and 3 g of oil were given per day as their publication indi-
cates, this would provide about 975 mg of LA per day in
the FO group (only 62 mg in the KO group). The intro-
duction of this variable is of importance as it is well
known that there is an antagonistic effect of raising LA on
EPA and DHA content in mammalian tissues [2,6,15]. A
simple calculation could then be made using the empirical
Table 2 Effect of multiple doses of fish oil on human erythrocyte EPA and DHA content after 5 months of
supplementation
EPA + DHA dose (mg/d) 0 300 600 900 1800
RBC EPA 0.47 ± 0.09a 0.91 ± 0.09b 1.23 ± 0.10bc 1.44 ± 0.09c 2.46 ± 0.09d
RBC DHA 3.87 ± 0.16a 5.30 ± 0.16b 5.60 ± 0.17bc 6.06 ± 0.16c 7.03 ± 0.16d
Doses which produced a statistically different fatty acid content were denoted by differing superscripts (data from Flock et al. ref 12).
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factor lowered the values for total n-3 PUFAs in the FO
case [15]. What is required for this calculation is the
LA, ALA, n-6 HUFA and n-3 HUFA intake values.
Since Ramprasath et al. performed their study in Canada,
EFA intake values available for Canadian women [16] were
used in this calculation. The calculation result is that add-
ing an additional 913 mg of LA in the FO supplement, or
about 0.365 en% LA, produces a 1% decrease in the n-3
expressed as a percentage of total HUFA (highly unsatur-
ated fatty acids). This factor must then be applied to the
values given by Ramprasath in their Tables two and three
for the “Total n-3 PUFA” in the FO group at the end-
point of the experiment [4]. Applying this correction to
these fatty acid values indicates that the FO values for
total n-3 PUFA would have been 6.69% (vs. 6.51%) in
plasma and 8.30% (vs. 8.04%) in erythrocytes had not the
additional LA been added to the FO capsules. Thus about
26 and 37% of the differences observed in plasma and
erythrocytes, respectively, between KO and FO could be
ascribed to this addition of linoleic acid into the FO. It is
unclear whether this would have resulted in a lack of a
statistical difference in the EPA and DHA content be-
tween the FO and KO groups but it would have made ob-
serving such a difference less likely.
It has been surmised that KO may be better absorbed
relative to FO as it is partly comprised of phospholipid
whereas FO products are mainly triglycerides. In fact, com-
mercial KO compositions can vary widely in phospholipid
content from as little as 19% up to 81% [17]. KO di- and
tri-glycerides can vary from about 13 to 34% and non-
esterified fatty acids can vary from 3.5 to as much as 36%.
A report of a third commercial KO source indicates that it
is composed of only 16% phospholipid, 24% triglyceride
and 60% of a “polar, non-phospholipid fraction [18] which
is composed mainly of cholesterol, mono- and diglycerides
and red pigment, mainly astaxanthin” [19]. Thus two of
the three commercial KO preparations had phospholipids
as a minor component. Some support can be found in the
literature for an increased efficacy for a phospholipid
source of PUFAs relative to triglycerides. In a single dosing
study, Wijendran et al found a better incorporation of a
stable isotope labeled phospholipid containing labeled
ARA relative to a triglyceride form [20]. However, such
single dose studies cannot be extrapolated to a chronic
case where supplements are taken daily and it is un-
known whether DHA incorporation into tissues wouldhave a similar sensitivity to the lipid form provided.
Only the equilibrium values of these essential fatty
acids in tissues are of relevance and clearly related to
health effects.
In some of the KO publications, it is stated that there
were no adverse effects observed but examination of the
data in the papers indicate otherwise. For example, in
the Ramprasath study, Table five indicates that subjects
in both the corn oil placebo and fish oil groups had one
incidence each of burping at a mild and moderate level
of intensity [4]. However, there were 4 and 3 incidences
at the mild/moderate levels of burping in the KO arm.
Similarly, aftertaste was noted as mild on three occa-
sions in the FO arm but 6 times in the KO arm and one
at the more intense level of moderate. No statistical ana-
lyses appear to have been performed and yet the abstract
concludes that “krill oil was well tolerated with no adverse
effects”. It is clear that these are not serious adverse effects
but they may well indicate sensory properties that are not
up to the standard of commercial FO. Similarly, Maki et al.
[7] indicate that the incidence of various gastrointestinal
side effects in comparison to menhaden oil are increased,
e.g., gas/bloating, 5 vs 0; flatulence, 9 vs 2; diarrhea, 5 vs 2.
The authors indicate that the increased incidence of gas/
bloating and flatulence in the KO group over that observed
in the fish oil group was statistically significant. In spite of
these observations, the authors state in the abstract that
“No significant differences for other safety variables were
noted, including adverse events”. Here again, these are not
serious adverse events but they are indeed adverse events
that can affect the quality of life when a supplement is
taken chronically.
There has been a recent animal study that has raised
some concern about possible KO kidney toxicity [18]. In
this study KO was compared to several fish oils (men-
haden (MO), salmon (SO) and tuna (TO)) as well as a
flaxseed oil (FO) and a corn oil (CO) control after feed-
ing to 4 wk old rats for a subsequent 8 wks as a 12% fat
diet. The authors summarized their findings by saying
“Rats fed MO, TO and SO had higher renal DHA and
EPA content that may optimize health by reduced in-
flammation through decreasing production of mediators
of inflammation, activation of transcription factors, and
inflammatory gene expression. In contrast, rats consum-
ing KO and to a lesser degree FO showed evidence of
renal calcification and tubulo-interstitial injury. This was
due to increased urinary P excretion associated with the
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ther studies are needed, susceptible individual should be
aware of a potential risk of increasing phospholipids
consumption on renal health”. (It is important to state
here that within this quotation, the FO is an abbrevi-
ation for flaxseed oil and not fish oil). These results were
obtained using a diet with 11.8 wt% as KO and this is a
dose that is unlikely to occur in human diets. Neverthe-
less, as the authors point out, “use of high doses of puri-
fied compounds is standard when assessing the safety of
compounds”.
In summary, a careful randomized, controlled trial is
needed in healthy adults to compare triglyceride forms
of long chain, omega-3 PUFAs as found in fish oils to
the phospholipid form found in KO. It is necessary to
adjust the FO EPA and DHA content to be equivalent to
the KO and to blend them to the same concentration as
the KO so that capsules could be made that match in
size and dosage. Furthermore, FO capsules should be
colored so that they are similar to the color of KO cap-
sules. A chronic study would then be carried out for at
least 4 wks and the primary endpoint being RBC or
plasma fatty acid content of EPA and DHA at the study
termination. Control over diet must be exerted to limit
fish intake during the trial and subjects with prior omega-3
supplement use or high fish intake must be excluded. Stat-
istical analyses would then be made to determine whether
there are differences in EPA/DHA content when an iden-
tical dose is given in the two different forms.
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